Neurotech Pharmaceuticals, Inc.
http://www.neurotechusa.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurotech Pharmaceuticals, Inc.
AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next
Outstanding Q1 growth in sales and profits have pleased the markets, and investors are now keen to hear more about AstraZeneca’s 2030 masterplan at its investor day next month.
IPO Gives Kyverna Cash To Maintain Lead In Autoimmune CAR-T Development
Kyverna CEO Peter Maag spoke with Scrip about the company’s five-year overnight success after its well-received IPO. Metagenomi and Telomir also went public in the US in smaller offerings.
AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?
Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.
Finance Watch: Alto, Fractyl Bring IPO Count To Four, So Far, In 2024
Public Company Edition: Alto Neuroscience and Fractyl Health grossed $128.6m and $110m, respectively, while FibroBiologics went public in a direct listing. Also, Vaxcyte grossed $862.5m in a follow-on offering, Immunocore grossed $350m in a note sale and Vera raised $287.5m.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Biomaterials
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice